Nephron Research analyst Thomas DeBourcy upgraded Azenta (AZTA) to Hold from Sell with a $31 price target
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZTA:
- Azenta, Inc. Reports Strong Fiscal 2025 Results
- Azenta, Inc. Reports Resilient Earnings Amid Challenges
- Azenta’s Strong Q4 Performance and Strategic Initiatives Drive Buy Rating and Increased Price Target
- Azenta’s Mixed Performance: Growth in Multiomics Amidst US Market Challenges Leads to Hold Rating
- Midday Fly By: Bitcoin slides, Lilly hits $1T market cap